RE: SPACs back from brink with NK cell therapy biotech's plans for blank-check merger29 Mar 2023 10:48
TP - upon meeting the Synairgen executives last June at the AGM I formed the opinion that they were genuine and honest people, who wouldn't knowingly do anything underhand which would result in a total-loss for shareholders. Rather the reverse in fact - whereas some shareholders might accept far less than the true "fair value" of SNG001 due to impatience or weariness, the Synairgen people I spoke to seemed very focused on reaching the MAXIMUM potential for the drug, even if it took that bit longer.
I don't profess to be the best judge of character and, nearly a year on, my impatience and weariness is ever-growing...but I do retain some trust in the BOD that they are doing the right thing behind the scenes and I try to remain as optimistic as I can, as I agree that this is the best course of action at present.
ATB & GLA